James Driscoll

Physician-Scientist; specializing in Hematologic Malignancies and Brain Tumors.

Sajjeev Jagannathan

I am a Sr.Research Associate in Dr.Driscoll’s lab. After graduating with a bachelor’s degree in Industrial biotechnology, I started my career as a traditionally trained Research Technician in Reliable laboratories. I later left the area and moved up to Michigan and enrolled in a Master’s program at University of Michigan. I pride myself about the research knowledge I gained when I worked as a Research assistant and I graduated with a thesis. With a Master’s degree, I joined The University of Cincinnati School of medicine as a Research Assistant. The majority of my work today is centered on pre-clinical drug studies and gene expression. My passion for Research is an interesting journey of discovery and learning, nurtured with enthusiasm, inspiration and self-motivation. I’m a Swiss Army knife; knowledgeable and curious about most things; expert in select areas. Over the years, I have mastered many molecular biology techniques that helps me design and execute experiments.

Nikhil Vad

I joined the Driscoll lab in November 2013 as a postdoctoral fellow and I’m currently conducting research on a novel dual PI3K/mTOR inhibitor against brain tumors. My other major research efforts include studies to identify and characterize mechanisms of drug resistance in circulating tumor cells isolated from the peripheral blood of multiple myeloma patients and healthy individuals. I have published 8 research articles as the first/corresponding author in peer-reviewed journals and currently serve as a peer reviewer for the International J of Cancer, Chemico-Biological Interactions, Journal of Pharmacology and Experimental Therapeutics, and Oxidative Medicine and Cellular Longevity. I graduated in 2009 from the Texas Tech University HSC with a Ph.D. in Pharmaceutical Sciences and then pursued a postdoctoral fellowship with the Developmental Therapeutics Program at the Texas Tech University Cancer Center prior to joining the Driscoll Laboratory.

Nitin Narayanan

I'm a graduate student working in Dr. Driscoll's lab. My research work primarily focuses on understanding the molecular mechanisms and also the therapeutic intervention of glioblastoma multiforme, a high grade brain tumor. The long term goal of my research work is to develop targeted therapies that would improve the overall and progression- free survival of brain tumor patients.

Mohamed Ahmed Yehya Abdel Malek

I’m an assistant lecturer in Clinical pathology Department, Faculty of Medicine, Assiut University, Egypt. I’m a visiting scholar. My research interests are in Leukemia , Lymphoma & Myeloma. My research work primarily focuses on targeting protein degradation pathways for therapeutic benefit in hematologic malignancies. Our long term goals are to develop an effective therapeutics to hematologic malignancies and to overcome resistance to current treatment modalities.​

Samer Alsidawi

I am an internal medicine resident at the University of Cincinnati volunteering in the lab of Dr.Driscoll. My research work focuses on investigating novel diagnostics and therapeutics for metastatic brain tumors. The role of microRNAs in the "seeding", growth and chemoresistance of brain metastases within the brain microenvironment, and targeting these miRNA signals are research areas that I continue to work on. The long term goals of my research would be to find the proper methods to apply this knowledge in the clinical setting to improve the quality of life and survival of patients with metastatic brain tumors.

Ehsan Malek

Fellow in the Hematology and Oncology Program at the University of Cincinnati College of Medicine.Internal Medicine Training at the University of Utah School of Medicine. Medical Degree from Shahid Behesti University of Medical Sciences

Saulius Girnius

I am an Assistant Professor of Medicine in the department of Hematology/Oncology and Bone Marrow Transplant at the University of Cincinnati. I have a special interest in plasma cell dyscrasia, including multiple myeloma, AL amyloidosis, and light chain deposition disease. I have been actively involved in clinical research and scholarly activities in plasma cell dyscrasias, having published numerous peer-reviewed journal articles, as well as review articles in prestigious journals such as the Journal of Clinical Oncology, Bone Marrow Transplantation, and Leukemia Supplements. I have presented at national and international hematology/oncology meetings including the American Society of Hematology (ASH) and the International Symposium of Amyloidosis. The treatment of multiple myeloma, as well as AL amyloidosis and light chain deposition disease has evolved significantly over the last decade toward the use of novel agents, as well as re-purposing of older agents. Because of this, disease management is becoming increasingly individualized and requires close collaboration between multiple members of the treatment team, physicians from numerous specialties, families and patients. This is the unique philosophy of care I bring to the University of Cincinnati Hematology/Oncology and Bone Marrow Transplant program.